Literature DB >> 15961552

Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.

György Sölétormos1, Axel Semjonow, Paul E C Sibley, Rolf Lamerz, Per Hyltoft Petersen, Walter Albrecht, Peter Bialk, Massimo Gion, Frank Junker, Hans-Peter Schmid, Hein Van Poppel.   

Abstract

BACKGROUND: The objectives of this study were to determine whether a single result for total prostate-specific antigen (tPSA) can be used confidently to guide the need for prostate biopsy and by how much serial tPSA measurements must differ to be significant. tPSA measurements include both analytical and biological components of variation. The European Group on Tumor Markers conducted a literature survey to determine both the magnitude and impact of biological variation on single, the mean of replicate, and serial tPSA measurements.
METHODS: The survey yielded 27 studies addressing the topic, and estimates for the biological variation of tPSA could be derived from 12 of these studies.
RESULTS: The mean biological variation was 20% in the concentration range 0.1-20 microg/L for men over 50 years. The biological variation means that the one-sided 95% confidence interval (CI) of the dispersion for a single tPSA result is approximately 33%. Three replicate samples with one analysis on each narrow the one-sided 95% CI for the mean concentration to approximately 20% and facilitate decisions on prostate biopsy. During monitoring of serial measurements, the change needed for significance is approximately 50% (P <0.05).
CONCLUSIONS: The biological variation of tPSA has implications for screening, diagnosis, and monitoring. Single measurements may not be sufficiently precise for screening and diagnosis. Replicate samples and calculation of the mean concentration may improve precision by reducing the dispersion. Monitoring of tPSA requires an estimate of either the change needed for significance or, alternatively, of the significance of the change.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961552     DOI: 10.1373/clinchem.2004.046086

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  31 in total

1.  [PSA 2010--the beginning of a new era in early detection of prostate cancer].

Authors:  C Börgermann; M Sieverding; P Fornara; M Graefen; P Hammerer; A Semjonow; F Schröder; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.

Authors:  Brant A Inman; Jingyu Zhang; Nilay D Shah; Brian T Denton
Journal:  BJU Int       Date:  2012-02-07       Impact factor: 5.588

3.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

4.  Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

Authors:  Gianluigi Taverna; Giorgio Bozzini; Fabio Grizzi; Mauro Seveso; Alberto Mandressi; Luca Balzarini; Federica Mrakic; Pietro Bono; Oliviero De Franceco; NicolòMaria Buffi; Giovanni Lughezzani; Massimo Lazzeri; Paolo Casale; Giorgio Ferruccio Guazzoni
Journal:  World J Urol       Date:  2015-10-19       Impact factor: 4.226

5.  Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance.

Authors:  Se Young Choi; Bumjin Lim; Yoon Soo Kyung; Yunlim Kim; Bong Min Kim; Byung Hee Jeon; Jae Chan Park; Young Woong Sohn; Jae Hyuk Lee; Ji-Hyun Uh; Seongsoo Jang; Choung-Soo Kim
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 6.  [How to use PSA in 2009].

Authors:  Anton Ponholzer; Franz Stoiber; Wolfgang Loidl; Michael Rauchenwald; Paul Schramek; Stephan Madersbacher
Journal:  Wien Med Wochenschr       Date:  2009

Review 7.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

8.  [Problems, objective, and substance of early detection of prostate cancer].

Authors:  C Börgermann; H Loertzer; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

Review 9.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

10.  Hematologic and Biochemical Biologic Variation in Laboratory Cats.

Authors:  Catherine Trumel; Céline Monzali; Anne Geffré; Didier V Concordet; Louise Hourqueig; Jean-Pierre D Braun; Nathalie H Bourgès-Abella
Journal:  J Am Assoc Lab Anim Sci       Date:  2016       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.